Navigation Links
NUVO announces third quarter 2008 financial results
Date:10/30/2008

ions of existing molecular penetration enhancers ("MPE(TM)s") with large numbers of potential drug formulations to measure their ability to permeabilize and permeate the skin. Nuvo's lead product Pennsaid(R), a topical non-steroidal anti-inflammatory drug (NSAID) utilizes the Company's technology to treat the symptoms of osteoarthritis of the knee locally. Nuvo intends to leverage its technologies to create a portfolio of topical and transdermal products targeting a variety of indications. Nuvo Research Inc. is a publicly traded company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development facility in San Diego, California. For more information, please visit http://www.nuvoresearch.com.

This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.

Summary financial statements attached:

NUVO RESEARCH INC.

CONSOLIDATED BALANCE SHEETS

As at As at

September 30, December 31,

2008 2007

Unaudited Audited

(thousands of Canadian dollars) $ $

-------------------------------------------------------------------------

ASSETS

CURRENT

Cash and cash equivalents 18,90
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System
2. Avaya Platinum Partner Merrill & Associates Announces Engineering and Application Strategy
3. Jenny Craig Announces Finalists for the 2008 Ideal Size Contest
4. WorldHeart Announces Effectiveness of Reverse Stock Split
5. XELR8 Holdings Announces Conference Call to Review Third Quarter Financial Results
6. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
7. Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital
8. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
9. Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
10. Blackboard Announces Launch of Beta Program
11. Wound Management Technologies, Inc. Announces Strategic Business Directions, Recent Conference Presentation, in Addition to Symposium Exhibit Plans for Las Vegas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 On October 22, CBS will ... skin diseases both fictional and real. The Charles ... organization committed to advocacy and philanthropy in the battle ... the opportunity to impart truth and clarity about this ... are many misconceptions about Morgellons Disease (MD) ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... reveals there may be a link between hardening of the ... with calcium deposits in the aorta were twice as likely ... in the heart were up to four times more likely ... 60 years or older, who had been diagnosed with having ...
... potential to yield treatments for several human diseases and ... announced they have created 17 new human embryonic stem ... researchers , which is offering the cells, will use ... Their team has been investigating the insulin-producing pancreatic beta ...
... ( an evolution specialist ), helped China's SARS Epidemiology ... fingerprinted virus samples from several dozen infected people and ... provides more evidence that SARS jumps from animals to ... of new cases is crucial, before viral strains have ...
... Ever since organ transplants began, steroids have played a ... their new organ. However, the treatment is not without ... to infections, high blood pressure, elevated blood cholesterol, and ... Belgium suggests children undergoing liver transplants may fare better ...
... has increased rapidly in the last half century, and ... about 50,000 Americans will be diagnosed with it this ... for women between the ages of 30 and 50,// ... yet that artificial sun tanning can be dangerous to ...
... studies have identified genetic activity that appears to be ... a person's perceptions of reality, emotions and thought processes. ... the world's population, typically surface during the late teens ... University in New York and colleagues identified two genes/// ...
Cached Medicine News:Health News:Scientists Have Traced How The SARS Virus evolved 2Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Gene Activity connected to Schizophrenia 2
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: PGLA) is ... data has been accepted for late breaking news,presentation by ... Progen will also be presenting the results of this ... (AACR),Annual Meeting 2007. , ,In expectation of having ...
... Good Safety Profile and Excellent,Pharmacokinetic Properties -, RESEARCH ... BioPharma, Inc., a clinical stage company developing and,commercializing ... today announced top-line results from a Phase I,clinical ... treatment,of depression and anxiety. In this study, Tyrima ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
30 degree angled tip with 45 mm tip opening. Made with lock. Manufactured in titanium....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Folding forceps used for L161U. Manufactured in titanium....
Medicine Products: